Health
Huntington’s Therapy Patient Reacts to Durability Concerns
A Huntington's disease patient remains optimistic despite questions about the long-term effectiveness of UniQure's gene therapy. The issue is significant for Wall Street investors.
Coverage timeline — 1 article
STAT News
Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street. They matter less to those directly affected by the disease.
2026-10-01 10:30 UTC